Regenera Pharma
Stage
Corporate Minority - II | AliveTotal Raised
$10MLast Raised
$10M | 5 yrs agoAbout Regenera Pharma
Regenera Pharma is developing a drug for the treatment of degenerative nerve diseases. Its first product is designed to treat a rare disease called nonarteritic anterior ischemic optic neuropathy (NAION), in which eye nerves die, causing blindness in the patient.
Missing: Regenera Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Regenera Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Regenera Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Regenera Pharma is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Regenera Pharma Patents
Regenera Pharma has filed 20 patents.
The 3 most popular patent topics include:
- Medicinal plants
- Neurological disorders
- Psychiatric diagnosis
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
9/7/2017 | 12/28/2021 | Diseases of the eye and adnexa, Rare diseases, Neurological disorders, Syndromes, Triterpenes | Grant |
Application Date | 9/7/2017 |
|---|---|
Grant Date | 12/28/2021 |
Title | |
Related Topics | Diseases of the eye and adnexa, Rare diseases, Neurological disorders, Syndromes, Triterpenes |
Status | Grant |
Latest Regenera Pharma News
Dec 5, 2022
New York, New York, UNITED STATES NEW YORK and TORONTO and HERZLIYA, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to announce the withdrawal of a class action lawsuit against it (the “Regenera Lawsuit”). The Regenera Lawsuit was described in the Company’s press release dated May 26, 2020 and in the Company's most recent Annual Report and Annual Information Form and it was primarily concerning a motion to certify, as a class action, a claim filed against the Company, its directors and its executive officers, alleging that the Company violated its obligation to publicly disclose certain events and developments which impacted the valuation of Regenera Pharma Ltd. (in which the Company held a 11.76% position during the time relevant to the claim). On December 2, 2022, the Tel Aviv District Court approved a consent motion to withdraw the Regenera Lawsuit, without any payment to the plaintiff from the Company. About InterCure (dba Canndoc) InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America. For more information, visit: http://www.intercure.co . Contact:
Regenera Pharma Frequently Asked Questions (FAQ)
Where is Regenera Pharma's headquarters?
Regenera Pharma's headquarters is located at Einstein 18, Ness Ziona.
What is Regenera Pharma's latest funding round?
Regenera Pharma's latest funding round is Corporate Minority - II.
How much did Regenera Pharma raise?
Regenera Pharma raised a total of $10M.
Who are the investors of Regenera Pharma?
Investors of Regenera Pharma include aMoon Fund and Intercure.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.